Focus: Tonix Pharmaceuticals is a publicly traded specialty pharmaceutical company focused on CNS disorders, particularly neurology. The company operates with 5,000+ employees and maintains a pipeline spanning fibromyalgia, PTSD, and infectious disease indications.
Profile data last refreshed 19h ago · AI intelligence enriched 4d ago
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
Tonix is a high-risk, high-reward play for pharma professionals seeking late-stage pipeline exposure and equity upside, but only suitable for candidates with tolerance for cash-burn volatility and realistic expectations about restructuring probability.
Generic muscle relaxant with loss of exclusivity; multiple ANDA filings indicate mature, commoditized product with limited growth.
Help build intelligence for Tonix Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tonix Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Duplicate ANDA entry; indicates portfolio breadth in generics but declining strategic importance.
Third ANDA cyclobenzaprine product; commodity generics portfolio with no differentiation.
Fourth ANDA cyclobenzaprine entry; post-LOE generic with minimal commercial upside.
Fifth ANDA cyclobenzaprine product; portfolio duplication suggests legacy generic footprint.
Sixth ANDA cyclobenzaprine entry; repetitive generics portfolio with low revenue contribution.
Recently launched NDA brand; backed by Medicare PBM coverage targeting 145M covered lives—primary commercial growth driver and key career visibility asset.
Seventh ANDA cyclobenzaprine; post-LOE generic with erosion risk from competition.
Eighth ANDA cyclobenzaprine entry; commodity product in crowded generic market.
Ninth ANDA cyclobenzaprine; post-LOE portfolio component with limited differentiation.
Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives - Stock Titan
Tonix Pharmaceuticals (NASDAQ: TNXP) secures PBM Medicare pact, targeting 145M TONMYA covered lives Stock Titan
Raymond James initiates Tonix Pharma stock coverage with strong buy - Investing.com
Raymond James initiates Tonix Pharma stock coverage with strong buy Investing.com
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 - GlobeNewswire
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 GlobeNewswire
Fibromyalgia drug developer Tonix plans 1x1 talks at infectious disease event - Stock Titan
Fibromyalgia drug developer Tonix plans 1x1 talks at infectious disease event Stock Titan
Insider Buying: Richard Stillwell Acquires Shares of Tonix Pharm - GuruFocus
Insider Buying: Richard Stillwell Acquires Shares of Tonix Pharm GuruFocus
Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage - Moomoo
Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage Moomoo
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo